Market Place
Sourcing Support
ASH: Roche offers glimpse at Columvi-Polivy combo in DLBCL
11 Dec 2023 //
FIERCE PHARMA
After approval in DLBCL, debate continues around benefit from Roche`s ADC Polivy
24 Aug 2023 //
ENDPTS
Roche guilty of serious marketing breach for Polivy website
14 Jul 2023 //
FIERCE PHARMA
Roche wins hard-fought approval for Polivy in earlier lymphoma
20 Apr 2023 //
FIERCE PHARMA
FDA adcomm votes 11-2 to expand Roche`s Polivy label in DLBCL
10 Mar 2023 //
ENDPTS
FDA raises questions in adcomm briefing docs for Roche`s Polivy label expansion
09 Mar 2023 //
ENDPTS
Genentech Presents Data for Polivy at ASH 2022
11 Dec 2022 //
BUSINESSWIRE
FDA accepts supplemental BLA for Roche’s Polivy combo
17 Aug 2022 //
THEPHARMALETTER
Genentech lymphoma treatment gets FDA approval
16 Aug 2022 //
LABIOTECH
EC approves Roche’s Polivy combination in previously untreated diffuse LBCL
26 May 2022 //
EXPRESS PHARMA
Roche delays Polivy`s 1L DLBCL filing as FDA asks for more data
25 Apr 2022 //
FIERCEPHARMA
Progression-Free Survival Boost Noted With Polatuzumab Vedotin Plus R-CHP
17 Dec 2021 //
CANCERNETWORK
Roche`s Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients
15 Dec 2021 //
BENZINGA
Roche’s Polivy combination reduced the risk of disease worsening or death by 27%
14 Dec 2021 //
GLOBENEWSWIRE
MorphoSys, Incyte Show Additional Real-World Data from RE-MIND2 Study
11 Dec 2021 //
BUSINESSWIRE
Chugai seeks Japanese approval for additional indication of Polivy for DLBCL
10 Dec 2021 //
PHARMABIZ
Roche`s Polivy combo shows 27% PFS benefit in first-line B-cell lymphoma
23 Nov 2021 //
FIRSTWORDPHARMA
Analyst jacks up Roche`s Polivy projection to $2.4B
07 Sep 2021 //
FIERCEPHARMA
Roche`s Polivy posts a big win in front-line DLBCL
10 Aug 2021 //
FIERCEPHARMA
Health Canada Grants Market Authorization to Polivy™
24 Sep 2020 //
BLOOMBERG
Chugai Files a New Drug Application for Polatuzumab Vedotin for the Treatment
30 Jun 2020 //
PRESS RELEASE
Polivy struck by NICE ‘no’
27 Feb 2020 //
PHARMATIMES
NICE rejects Roche`s new cancer med Polivy on lack of long-term evidence
27 Feb 2020 //
FIERCE PHARMA
Polatuzumab Vedotin Achieved Primary Endpoint in the Japanese Ph II study
13 Feb 2020 //
PRESS RELEASE
EU clears Roche`s Polivy for certain lymphomas
22 Jan 2020 //
PHARMA TIMES
Seattle Genetics Achieves Milestone Following E.C Approval of Polivy
21 Jan 2020 //
BUSINESS WIRE
AllianceRx Walgreens Prime Issues Updated List of New Specialty Drugs
16 Aug 2019 //
PR NEWSWIRE
Roche touts phase 2 Gazyva data in lupus patients
12 Jun 2019 //
FIERCE PHARMA
Roche snags first-in-class FDA nod for lymphoma drug Polivy
11 Jun 2019 //
FIERCE PHARMA
Genentech`s Polatuzumab vedotin-PIIQ Receives Approval in US
10 Jun 2019 //
FDA
As generic competition stutter sales of top oncology drugs
19 Feb 2019 //
ENDPTS
Gilead locks in Daniel O’Day as CEO, tapping the Roche vet to rejuvenate growth
11 Dec 2018 //
ENDPTS
